Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma-Reference-Cited by-同舟云学术

Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma

Published:2016-05-26 Issue:21 Volume:127 Page:2561-2568
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Baz Rachid C.¹,Martin Thomas G.²,Lin Hui-Yi³,Zhao Xiuhua³,Shain Kenneth H.¹,Cho Hearn J.⁴,Wolf Jeffrey L.²,Mahindra Anuj²,Chari Ajai⁴,Sullivan Daniel M.⁵,Nardelli Lisa A.¹,Lau Kenneth⁴,Alsina Melissa⁵,Jagannath Sundar⁴

Affiliation:

1. Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;

2. Myeloma Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA;

3. Department of Biostatistics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;

4. Multiple Myeloma Program, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY; and

5. Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Abstract

Key Points PomCyDex results in a higher overall response rate than pomalidomide and dexamethasone. PomCyDex is an effective, all oral regimen for refractory myeloma patients.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/127/21/2561/1393412/2561.pdf

Reference23 articles.

1. Cancer statistics, 2014.;Siegel;CA Cancer J Clin,2014

2. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.;Kumar;Leukemia,2012

3. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.;Dimopoulos;N Engl J Med,2007

4. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.;Weber;N Engl J Med,2007

5. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.;Rajkumar;J Clin Oncol,2008

Cited by 139 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical outcomes of pomalidomide‐based and daratumumab‐based therapies in patients with relapsed/refractory multiple myeloma: A real‐world cohort study in China;Cancer Medicine;2024-05

2. Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial;Nature Medicine;2024-01-04

3. Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2023-12

4. A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma After Lenalidomide Exposure;Clinical Lymphoma Myeloma and Leukemia;2023-11

5. Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170);Frontiers in Oncology;2023-10-25